Layfield Christopher, Rose John, Alford Aaron, Snyder Susan R, Apple Fred S, Chowdhury Farah M, Kontos Michael C, Newby L Kristin, Storrow Alan B, Tanasijevic Milenko, Leibach Elizabeth, Liebow Edward B, Christenson Robert H
Battelle Memorial Institute, USA.
Battelle Memorial Institute, USA.
Clin Biochem. 2015 Mar;48(4-5):204-12. doi: 10.1016/j.clinbiochem.2015.01.014. Epub 2015 Feb 7.
This article is a systematic review of the effectiveness of four practices (assay selection, decision point cardiac troponin (cTn) threshold selection, serial testing, and point of care testing) for improving the diagnostic accuracy Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) in the Emergency Department.
The CDC-funded Laboratory Medicine Best Practices (LMBP) Initiative systematic review method for quality improvement practices was used.
The current ACC/AHA guidelines recommend using cardiac troponin assays with a 99th percentile upper reference limit (URL) diagnostic threshold to diagnose NSTEMI. The evidence in this systematic review indicates that contemporary sensitive cTn assays meet the assay profile requirements (sensitivity, specificity, PPV, and NPV) to more accurately diagnose NSTEMI than alternate tests. Additional biomarkers did not increase diagnostic effectiveness of cTn assays. Sensitivity, specificity, and NPV were consistently high and low PPV improved with serial sampling. Evidence for use of point of care cTn testing was insufficient to make recommendation, though some evidence suggests that use may result in reduction to patient length of stay and costs.
Based on the review of and the LMBP(TM) A-6 Method criteria, we recommend the use of cardiac troponin assays without additional biomarkers using the 99th percentile URL as the clinical diagnostic threshold for the diagnosis of NSTEMI. We recommend serial sampling with one sample at presentation and at least one additional second sample taken at least 6h later to identify a rise or fall in the troponin level. No recommendation is made either for or against the use of point of care tests.
The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry (CDC/ATSDR).
本文是对四种方法(检测方法选择、决策点心肌肌钙蛋白(cTn)阈值选择、系列检测和即时检测)在急诊科提高非ST段抬高型心肌梗死(NSTEMI)诊断准确性有效性的系统评价。
采用疾病预防控制中心资助的实验室医学最佳实践(LMBP)计划中用于质量改进实践的系统评价方法。
当前美国心脏病学会/美国心脏协会(ACC/AHA)指南推荐使用第99百分位上限参考值(URL)诊断阈值的心肌肌钙蛋白检测方法来诊断NSTEMI。本系统评价中的证据表明,当代灵敏的cTn检测方法符合检测方法特征要求(灵敏度、特异性、阳性预测值和阴性预测值),比其他检测方法能更准确地诊断NSTEMI。其他生物标志物并未提高cTn检测方法的诊断有效性。灵敏度、特异性和阴性预测值始终较高,但通过系列采样可提高较低的阳性预测值。即时cTn检测的使用证据不足以给出推荐意见,不过一些证据表明使用即时检测可能会缩短患者住院时间并降低费用。
基于对LMBP(TM)A - 6方法标准的审查,我们建议使用第99百分位URL作为临床诊断阈值且不添加其他生物标志物的心肌肌钙蛋白检测方法来诊断NSTEMI。我们建议在就诊时采集一个样本,并至少在6小时后再采集至少一个额外的样本进行系列采样,以确定肌钙蛋白水平的升高或降低。对于即时检测的使用,不给出支持或反对意见。
本文中的研究结果和结论为作者的观点,并不能必然代表疾病预防控制中心/有毒物质与疾病登记署(CDC/ATSDR)的官方立场。